Czech and Slovak spirapril intervention study (CASSIS)

Widimský, Jiří; Kremer, Hans-Joachim; Jerie, P; Uhlír, O

doi:10.1007/bf00192366

Cited by 20 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,21–77 The majority were multicenter, double-blind, placebo-controlled trials, including between 28 and 8399 patients with a mean follow-up duration ranging from 8 weeks to 4 years. The treatment classes assessed included ACEI, BB, ARB, MRA, and ARNI.…”

Section: Resultsmentioning

confidence: 99%

“…A sensitivity analysis was also performed that ignored concomitant therapies and evaluated how ARNI monotherapy was compared with ACEI and ARB monotherapies (Figure 3). 7,21–45 …”

Section: Resultsmentioning

confidence: 99%

“…ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; CASSIS, Czech and Slovak Spirapril Intervention Study; CHARM-alternative, Candesartan in Heart Failure–Assessment of Mortality and Morbidity Alternative; CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; ELITE, Evaluation of Losartan in the Elderly Study; FEST, Fosinopril Efficacy/Safety Trial; HEAVEN, Heart Failure Valsartan Exercise Capacity Evaluation; MHFT, Munich Mild Heart Failure Trial; PARADIGM-HF, Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) With ACEI (Angiotensin–Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure; PLBO, placebo; REPLACE, Replacement of Angiotensin Converting Enzyme Inhibition; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunction; SOLVD-prevent, Studies of Left Ventricular Dysfunction–Prevention Trial; SOLVD-treat, Studies of Left Ventricular Dysfunction–Treatment Trial; SPICE, Study of Patients Intolerant of Converting Enzyme Inhibitors; and STRETCH, Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure. 7,21–45 …”

Section: Resultsmentioning

confidence: 99%

“…Distribution of potential treatment effect modifiers: A , Duration of follow-up 7,21–77 ; B , NYHA class at baseline 7,21–77 ; C , LVEF at baseline. 7,21–77 AREA-IN CHF indicates Anti-Remodelling Effect of Canrenone in Patients With Mild Chronic Heart Failure; BEST, Beta-Blocker Evaluation of Survival Trial; CARMEN, The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial; CASSIS, Czech and Slovak Spirapril Intervention Study; CHARM-added, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity–Added; CHARM-alternative, Candesartan in Heart Failure–Assessment of Mortality and Morbidity Alternative; CIBIS, Cardiac Insufficiency Bisoprolol Study; CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival; ELITE, Evaluation of Losartan in the Elderly Study; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; ENECA, Efficacy of Nebivolol in the Treatment of Elderly Patients With Chronic Heart Failure as Add-On Therapy to ACE Inhibitors or Angiotensin II Receptor Blockers, Diuretics, and/or Digitalis; FEST, Fosinopril Efficacy/Safety Trial; HEAVEN, Heart Failure Valsartan Exercise Capacity Evaluation; LVEF, left ventricular ejection fraction; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; MHFT, Munich Mild Heart Failure Trial; MIC, Metoprolol in Patients With Mild to Moderate Heart Failure: Effects on Ventricular Function and Cardiopulmonary Exercise Testing; MOCHA, Multicenter Oral Carvedilol Heart Failure Assessment; NR, not reported; NYHA, New York Heart Association; PARADIGM-HF, Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) With ACEI (Angiotensin–Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure; PRECISE, Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise; RALES, Randomized Aldactone Evaluation Study; REPLACE, Replacement of Angiotensin Converting Enzyme Inhibition; RESOLVD, Randomized Evaluation of Strategies for Left Ventricular Dysfunction; SOLVD-prevent, Studies of Left Ventricular Dysfunction–Prevention Trial; SOLVD-treat, Studies of Left Ventricular Dysfunction–Treatment Trial; SPICE, Study of Patients Intolerant of Converting Enzyme Inhibitors; STRETCH, Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure; SYMPOXYDEX, Sympathetic and Oxydative Stress Kredex Study; and Val-HeFT, Valsartan Heart Failure Trial.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction

Burnett

Earley

Voors

et al. 2017

Circ: Heart Failure

197

152

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…A sensitivity analysis was also performed that ignored concomitant therapies and evaluated how ARNI monotherapy was compared with ACEI and ARB monotherapies (Figure 3). 7,21–45 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction

Burnett

Earley

Voors

et al. 2017

Circ: Heart Failure

197

152

View full text Add to dashboard Cite

show abstract

“…Seventeen studies [ 3 – 6 , 8 – 11 , 14 , 24 , 32 , 35 , 36 , 38 , 40 – 42 ] reported the effectiveness of ACEIs for CV mortality in a total of 28,302 HF patients with moderate heterogeneity in overall analysis (I 2 = 51%, p = 0.009). ACEIs were associated with a statistically significant 14% reduction in CV mortality (RR: 0.86, 95% CI: 0.78–0.94, p = 0.001, Fig.…”

Section: Resultsmentioning

confidence: 99%

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials

Tai

Gan

Zou

et al. 2017

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundHeart failure (HF) remains a significant cause of morbidity and mortality. Multiple trials over the past several years have examined the effects of both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocardial infarction and in chronic heart failure. Yet, there is still confusion regarding the relative efficacy of rennin-angiotensin-aldosterone system (RAAS) inhibition. Our study was conducted to assess efficacy of ACEIs and ARBs in reducing all-cause and cardiovascular mortality in heart failure patients.MethodsWe included randomized clinical trials compared ACEIs and ARBs treatment (any dose or type) with placebo treatment, no treatment, or other anti-HF drugs treatment, reporting cardiovascular or total mortality with an observation period of at least 12 months. Data sources included Pubmed, EMBASE, the Cochrane Central Register of Controlled Trials. Dichotomous outcome data from individual trials were analyzed using the risk ratio measure and its 95%CI with random-effects/ fixed-effects models. We performed meta-regression analyses to identify sources of heterogeneity. All-cause mortality and CV mortality were thought to be the main outcomes.ResultsA total of 47,662 subjects were included with a mean/median follow-up ranged from 12 weeks to 4.5 years. Of all 38 studies, 32 compared ACEIs with control therapy (included 13 arms that compared ACEIs with placebo, 10 arms in which the comparator was active treatment and 9 arms that compared ACEIs with ARBs), and six studies compared ARBs with placebo. ACEIs treatment in patients with HF reduced all-cause mortality to 11% (risk ratio (RR): 0.89, 95% confidence interval (CI): 0.83–0.96, p = 0.001) and the corresponding value for cardiovascular mortality was 14% (RR: 0.86, 95% CI: 0.78–0.94, p = 0.001). However, ARBs had no beneficial effect on reducing all-cause and cardiovascular mortality. In head-to-head analysis, ACEIs was not superior to ARBs for all-cause mortality and cardiovascular deaths.ConclusionsIn HF patients, ACEIs, but not ARBs reduced all-cause mortality and cardiovascular deaths. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.Electronic supplementary materialThe online version of this article (10.1186/s12872-017-0686-z) contains supplementary material, which is available to authorized users.

show abstract

Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction

Batchelor

Tie²,

Romero³

et al. 2023

The American Journal of Cardiology

View full text Add to dashboard Cite

Czech and Slovak spirapril intervention study (CASSIS)

Cited by 20 publications

References 27 publications

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials

Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction

Contact Info

Product

Resources

About